Ambrx Biopharma American Financials

AMAMDelisted Stock  USD 15.73  0.71  4.73%   
Based on the key measurements obtained from Ambrx Biopharma's financial statements, Ambrx Biopharma American is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.
  
Understanding current and past Ambrx Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ambrx Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Ambrx Biopharma's assets may result in an increase in income on the income statement.

Ambrx Biopharma Stock Summary

Ambrx Biopharma competes with Immix Biopharma, Cns Pharmaceuticals, Sonnet Biotherapeutics, Enveric Biosciences, and Elevation Oncology. Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company was incorporated in 2003 and is headquartered in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 81 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS02290A1025
Business Address10975 North Torrey
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteambrx.com
Phone858 875 2400
CurrencyUSD - US Dollar

Ambrx Biopharma Key Financial Ratios

Ambrx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ambrx Biopharma's current stock value. Our valuation model uses many indicators to compare Ambrx Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ambrx Biopharma competition to find correlations between indicators driving Ambrx Biopharma's intrinsic value. More Info.
Ambrx Biopharma American is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Ambrx Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Ambrx Biopharma Market Pulse

 Quote15.73
 Change(%)  4.73 
 Change0.71 
 Open15.02
 Low14.91
 High15.99
 Volume0
 ExchangeNASDAQ

Ambrx Biopharma December 2, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Ambrx Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ambrx Biopharma American. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ambrx Biopharma American based on widely used predictive technical indicators. In general, we focus on analyzing Ambrx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ambrx Biopharma's daily price indicators and compare them against related drivers.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Ambrx Stock

If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume